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ABSTRACT
Theprevalence of blaCTX-M, blaTEMand blaSHV genes
among extended-spectrum b-lactamase (ESBL)-
producing clinical isolates of Escherichia coli
(n = 50) and Klebsiella spp. (n = 50) from Lebanon
was 96%, 57% and 67%, and 40%, 82% and 84%,
respectively. Genotyping revealed that the clonal
diversitywasunrelated to thepresenceof blagenes.
Sequence analysis of 16 selected isolates identiﬁed
the blaCTX-M-15, blaTEM-1, blaOXA-1 and six blaSHV
genes, as well as the gene encoding the quinolone-
modifying enzyme AAC(6¢)-Ib-cr. The genes
encoding CTX-M-15 and AAC(6¢)-Ib-cr were
carried on a 90-kb plasmid of the pC15-1a or
pCTX-15 type, which transferred both ESBL pro-
duction and quinolone resistance from donors to
transconjugants.
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Although geographical variations exist, Gram-
negative bacteria producing extended-spectrum
b-lactamases (ESBLs) have become an increasing
problem worldwide [1]. In Lebanon, the preva-
lence of ESBL-producing isolates reached 8%
among Escherichia coli and 20% among Klebsiella
spp. in 2005 [2]. Until recently, TEM- and SHV-
derived enzymes have been the ESBLs encoun-
tered most commonly in E. coli and Klebsiella spp.
However, CTX-M ESBLs have become more
frequent, particularly in E. coli, during the past
decade [3]. Given the scarcity of data from
Lebanon [4,5], the aim of the present study was
to characterise ESBL-producing isolates of E. coli
and Klebsiella spp. at the molecular level in a non-
outbreak setting.
Clinical isolates of ESBL-producing E. coli
(n = 50) and Klebsiella spp. (n = 50) were collected
at the American University of Beirut Medical
Center during 1997–2002 and 2004–2005. ESBL
production was conﬁrmed using ceftazidime ⁄
clavulanate and cefotaxime ⁄ clavulanate disks
according to CLSI recommendations [6]. DNA
was extracted using the GFX Genomic Blood DNA
Puriﬁcation Kit (Amersham Pharmacia Biotech,
Piscataway, NJ, USA) according to the manufac-
turer’s guidelines. Each isolate was genotyped by
random ampliﬁed polymorphic DNA (RAPD)
analysis using a Ready-To-Go RAPD Analysis Kit
(Amersham Pharmacia Biotech) according to the
manufacturer’s recommendations.
All isolates were screened by PCR for blaTEM,
blaSHV and blaCTX-M genes using primers CTX-M-
1-F and CTX-M-15-R for blaCTX-M genes (873 bp)
[4], OT-3 and OT-4 for blaTEM genes (858 bp) [7],
and SHV-F and SHV-R for blaSHV genes (795 bp)
[5]. In addition, on the basis of the bla genes
detected, 16 isolates (eight E. coli and eight Kle-
bsiella spp.) were selected for screening and
subsequent sequencing analysis of qnrA (primers
QP1 and QP2) [8], qnrB (primers FQ1 and FQ2
[9]), qnrS (primers QnrS-A2 and QnrS-B2 [10]),
class I integrons (5¢-CS and 3¢-CS [11]), class II
integrons (Igr2-f and Igr2-r [12]), blaSHV (primers
SHV-FOR and SHV-REV [13]), aac(6¢)-Ib-cr [14],
blaOXA-1 [15], blaTEM (primers LCM1 and LCM2
[16]), blaCTX-M (primers CTX-MA1 and CTX-MA2
[17]) and ISEcp1B (primers CTX-MA2 [17] and
PROM+ [18]), as well as plasmid incompatibility
typing (Inc FII, primers CA 1 and OR 1 [19]).
All ampliﬁcations were performed as described
previously [5]. Amplicons were detected follow-
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ing electrophoresis on agarose gels, and were
photographed using an Olympus 3.0 camera
(Olympus, Tokyo, Japan) and the Doc-It program
(Ultra-Violet Products, Cambridge, UK). The
amplicons of the 16 selected isolates were puriﬁed
using a QIAquick PCR Puriﬁcation Kit (Qiagen,
Valencia, CA, USA) and were then sequenced
in both directions using Big-Dye 3.1 chemistry
(PE Biosystems, Foster City, CA, USA) and an
ABI 31000 automated sequencer (Applied Bio-
systems, Warrington, UK). Sequence data were
analysed using Seqman software (DNAStar Inc.,
Madison, WI, USA) [20].
Conjugation experiments were performed with
the 16 selected isolates using E. coli J53 (sodium
azide-resistant) as the recipient on MacConkey
agar containing sodium azide 100 mg ⁄L and
cefotaxime 2 mg ⁄L. Plasmids were extracted from
donor isolates and transconjugants using a
Qiagen Midi Plasmid Kit, (Qiagen), visualised
following electrophoresis on agarose 1% w ⁄ v
gels, and photographed as described above. Anti-
microbial susceptibility tests on E. coli J53 trans-
conjugants and PCR analysis of the genes carried
by the extracted plasmids were performed to
conﬁrm plasmid transfer from the donors to the
recipients [20].
The majority (96.1%) of E. coli isolates har-
boured a blaCTX-M gene; blaSHV and blaTEM genes
were detected less frequently (66.7% and 56.9%,
respectively). All three types of b-lactamase gene
were found concomitantly in 45.1% of E. coli
isolates. A blaSHV gene was most common in
Klebsiella spp. (84.1%), while blaTEM and blaCTX-M
genes occurred in 82.0% and 40.0% of isolates,
respectively; only 24.0% of the Klebsiella spp.
isolates harboured all three resistance genes.
These results are in accord with previous studies
describing the increasing global prevalence of
CTX-M enzymes [3], but a previous study in
Lebanon [4] failed to detect any blaCTX-M genes,
probably because of geographical variations in
the distribution of plasmid-encoded enzymes.
Table 1 shows the molecular characteristics of
the 16 selected isolates. All except K6 and K38
harboured the blaCTX-M-15 gene, the blaOXA-1 gene,
and the gene encoding the quinolone-modifying
enzyme AAC(6¢)-Ib-cr. The blaTEM-1 gene was
detected in 12 isolates and the blaSHV gene in
nine isolates (one E. coli and eight Klebsiella spp.),
with six different blaSHV types.
Conjugation experiments revealed that blaCTX-M-15
and the mobilising insertion sequence ISEcp1
were transferred to all the transconjugants, ren-
dering them resistant to third-generation cepha-
losporins (Table 1). The quinolone-modifying
enzyme AAC(6¢)-Ib-cr was also transferable,
increasing the resistance of transconjugants to
ciproﬂoxacin and norﬂoxacin, but not to nalidixic
acid. Class I integrons were detected in transcon-
Table 1. Molecular characteristics of 16 selected isolates of Escherichia coli and Klebsiella spp.
Isolate qnrA ⁄B qnrS AAC(6¢)-Ib AAC(6¢)-Ib-cr
CTX-M-15/







E11 ) ) ) + + + + ) + ) ) ND
E12 ) ) ) + + + + ) ) + +
pC15-1a
AMX ⁄CPD ⁄ATM ⁄CAZ ⁄GEN ⁄KAN
E13 ) ) ) + + ) + ) + + ) ND
E17 ) ) ) + + + + ) + + +
pCTX-15
AMX ⁄CPD ⁄ATM ⁄GEN ⁄KAN ⁄TRI
E18 ) ) ) + + ) + ) + + +
pCTX-15
AMX ⁄CPD ⁄ATM ⁄CAZ ⁄KAN
E23 ) ) ) + + ) + ) + + ) ND
E26 ) ) ) + + ) + ) + + +
pCTX-15
AMX ⁄CPD ⁄ATM ⁄CAZ ⁄KAN
E42 ) ) ) ) ) ) ) 12 ) ) ) ND
K3 ) ) ) + + + + 5 + + +
Not readable
AMX ⁄CPD ⁄ATM ⁄CAZ ⁄GEN ⁄KAN
K6 ) ) + ) ) ) ) 12 + ) ) ND
K13 ) ) ) + + + + 1 + + +
pC15-1a
AMX ⁄CPD ⁄ATM ⁄CAZ ⁄GEN ⁄KAN
K16 ) ) ) + + + + 28 ) ) +
Otherb
ND
K38 ) ) + ) ) ) ) 12 + ) ) ND
K7 ) ) ) ) + ) ) 77 + ) ) ND
K10 ) ) ) ) + ) ) 11 + ) ) ND
K14 ) ) ) ) ) ) ) 12 ) ) ) ND
aTransconjugant HpaI digest proﬁle as deﬁned by Boyd et al. [22].
bNot pC15-1a or pCTX-15.
AMX, amoxycillin; CPD, cefpodoxime; ATM, aztreonam; CAZ, ceftazidime; GEN, gentamicin; KAN, kanamycin; TRI, trimethoprim; ND, not determined.
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jugants derived from E17 and K16, but the blaTEM-1
and blaSHV genes were not transferable by conju-
gation to E. coli J53, indicating that they are
probably chromosomally encoded. Analysis
of transconjugants conﬁrmed that the genetic
determinants of AAC(6¢)-Ib-cr, class I integrons,
CTX-M-15 and ISEcp1 were encoded on a large
90-kb plasmid. Restriction digest analysis (using
HpaI) of the transferred plasmids indicated that
most were indistinguishable from the pC15-1a
or pCTX-15 plasmids described previously. The
antimicrobial resistances transferred to ﬁve trans-
conjugants are shown in Table 1.
RAPD analysis revealed a range of banding
proﬁles among both the E. coli (18 proﬁles) and
the Klebsiella spp. (15 proﬁles) isolates. No asso-
ciation was found between the RAPD proﬁles and
the b-lactamase genes carried by the isolates,
indicating that antimicrobial resistance is proba-
bly acquired through horizontal plasmid trans-
mission. These ﬁndings are commensurate with
those of previous studies [21]. The ﬁnding of the
transferable quinolone resistance gene AAC(6¢)-
Ib-cr, together with ESBL genes, on plasmids from
ten of 13 isolates is of particular concern, since use
of either quinolones or extended-spectrum
b-lactams would provide a selective advantage
for these bacteria.
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ABSTRACT
Bordetella spp. are not normally included when
considering the opportunistic bacterial species
that are typically involved in respiratory tract
infections in individuals with cystic ﬁbrosis (CF).
By using a combination of bacterial genotyping
and 16S rDNA sequencing, Bordetella spp. were
identiﬁed in cultures obtained from 43 individu-
als with CF. Most (n = 23) patients were infected
with Bordetella bronchiseptica ⁄ parapertussis; ﬁve
were infected with Bordetella hinzii, four with
Bordetella petrii, three with Bordetella avium, and
eight with unidentiﬁed Bordetella spp. Consider-
ation should be given to the presence of these
organisms in the evaluation of CF sputum
cultures.
Keywords 16S rDNA sequencing, Bordetella spp.,
cystic ﬁbrosis, rep-PCR, respiratory tract infection,
sputum
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Cystic ﬁbrosis (CF) is an autosomal recessive
disease, characterised by defective chloride ion
channels that result in multi-organ dysfunction,
most notably affecting the respiratory tract. The
alteration in the pulmonary environment is asso-
ciated with increased susceptibility to bacterial
infection. Recent advances in bacterial taxonomy
and improved microbial identiﬁcation systems
have led to an increasing recognition of the
diversity of bacterial species involved in CF lung
infection. Many such species are opportunistic
human pathogens, some of which are rarely
found in other human infections [1]. Processing
of CF respiratory cultures therefore employs
selective media and focuses on detection of
uncommon human pathogens. In recent years,
the use of molecular methods (e.g., species-spe-
ciﬁc PCRs and assays based on identifying
restriction fragment length polymorphisms) has
complemented the diagnostic capacity of routine
phenotypic analyses. The present study describes
the use of molecular methods to identify Bordetella
spp. in respiratory tract cultures from 43 patients
with CF.
The 43 bacterial isolates included in the study
were recovered between June 2001 and June 2007
from sputum cultures obtained from 43 CF
patients receiving care in 19 treatment centres in
the USA. All isolates were sent to the Burkholderia
cepacia Research Laboratory and Repository
(BcRLR; University of Michigan, Ann Arbor,
Michigan, USA) for microbiological evaluation.
Reference strains comprised Achromobacter xylos-
oxidans ATCC 9220,Alcaligenes faecalisATCC 337,
Alcaligenes faecalis subsp. faecalis LMG 1229T,
Alcaligenes sp. ATCC 21030, Bordetella avium
LMG 1852T, Bordetella bronchiseptica LMG 1232T,
Bordetella hinzii LMG 13500, Bordetella holmesii
LMG 15945T, Bordetella parapertussis LMG 14449T,
Bordetella pertussis LMG 14455T and Bordetella
trematum LMG 13506T. B. pertussis was grown on
Regan–Lowe charcoal agar (BBL, Franklin Lakes,
NJ, USA). All other bacterial isolates were grown
aerobically on plates containing Mueller–Hinton
broth (Becton Dickinson, Cockeysville, MD, USA)
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